Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 1890Carcinoma, Non-Small-Cell Lung 1350Prostatic Neoplasms 983Colorectal Neoplasms 852Multiple Myeloma 741Leukemia, Myeloid, Acute 725Neoplasms 693Lung Neoplasms 680Neoplasm Metastasis 643Lymphoma 579Carcinoma, Hepatocellular 572Pancreatic Neoplasms 568Stomach Neoplasms 523Leukemia 511Recurrence 492Leukemia, Lymphocytic, Chronic, B-Cell 459Precursor Cell Lymphoblastic Leukemia-Lymphoma 452Melanoma 451Lymphoma, Non-Hodgkin 443Ovarian Neoplasms 429Lymphoma, Large B-Cell, Diffuse 423Squamous Cell Carcinoma of Head and Neck 416Myelodysplastic Syndromes 416Head and Neck Neoplasms 406Brain Neoplasms 403Rectal Neoplasms 397Glioblastoma 375Carcinoma, Renal Cell 350Hodgkin Disease 338Esophageal Neoplasms 337

Interventions

tislelizumab 1nedaplatin 1Radiotherapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × OTHER × Immunotherapy Esophagus Cancer × Clear all
NCT05515315 2024-02-07

Induction Tislelizumab Combined With Chemotherapy Followed by Definitive Chemoradiotherapy in the Treatment of Locally Unresectable Esophageal Squamous Cell Carcinoma

Fuzhou General Hospital

Phase 2 Recruiting
93 enrolled
Gastrointestinal

Immunotherapy Esophagus Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡